. Author manuscript; available in PMC: 2026 Mar 7.

Published in final edited form as: Am J Gastroenterol. 2025 Mar 7;120(11):2520–2528. doi: 10.14309/ajg.0000000000003383

Table 5.

Frequency of dysplasia in those with persistent Barrett’s esophagus (BE) after ultrashort BE on index endoscopy, negative BE after USBE-IE, no follow-up after USBE on index endoscopy, and normal segment BE on index endoscopy.

Highest Detected Dysplasia	Persistent BE after USBE on Index Endoscopy (n=86)			Negative BE after USBE on Index Endoscopy (n=66)		No Follow-Up Endoscopy after USBE on Index Endoscopy (n=15)	Longer Segment BE on Index Endoscopy (n=572)
Nondysplastic BE	48 (55.8%)			57 (85.1%)		12 (85.7%)	277 (48.4%)
BE Indefinite for Dysplasia	24 (27.9%)			9 (13.4%)		2 (14.3%) prevalent	164 (28.6%)
BE Indefinite for Dysplasia	19 at index EGD		5 on follow-up	6 at index EGD	3 on follow-up	2 (14.3%) prevalent	87 prevalent	77 incident
BE with Low-Grade Dysplasia	8 (9.3%)			0		1 (1.5%) at index EGD	98 (17.1%)
BE with Low-Grade Dysplasia	2 at index EGD	6 on follow-up		0		1 (1.5%) at index EGD	32 at index EGD	66 on follow-up
BE with High-Grade Dysplasia	5 (5.8%)			0		0	22 (3.6%)
BE with High-Grade Dysplasia	3 at index EGD	2 on-follow-up		0		0	7 at index EGD	15 on follow-up
Esophageal Adenocarcinoma	1 (1.2%) on-follow-up			0		0	11 (1.9%)
Esophageal Adenocarcinoma	1 (1.2%) on-follow-up			0		0	1 at index EGD	10 on follow-up

Abbreviations: BE=Barrett’s esophagus. NDBE=nondysplastic BE.